.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,880,283

« Back to Dashboard
Patent 5,880,283 protects ZYMAXID and ZYMAR and is included in two NDAs. There have been zero Paragraph IV challenges on Zymaxid and Zymar There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for ZYMAXID has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 5,880,283

Title: 8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
Abstract:The invention provides 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid sesquihydrate with excellent stability represented by a following formula (1), ##STR1## and process for producing the same.
Inventor(s): Matsumoto; Toyomi (Kamiina-gun, JP), Hara; Masamoto (Okaya, JP), Miyashita; Kunio (Okaya, JP), Kato; Yukihiro (Okaya, JP)
Assignee: Kyorin Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/860,325
Patent Claim Types:
see list of patent claims
Compound; Process;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 6th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
ZYMAXID
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC022548-001May 18, 2010RXYes5,880,283*PED► subscribeY
Allergan
ZYMAR
gatifloxacin
SOLUTION/DROPS;OPHTHALMIC021493-001Mar 28, 2003RXYes5,880,283*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,880,283

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan6-335569Dec 21, 1994
PCT Information
PCT FiledDecember 05, 1995PCT Application Number:PCT/JP95/02477
PCT Publication Date:June 27, 1996PCT Publication Number: WO96/19472

International Patent Family for Patent: 5,880,283

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria216381► subscribe
Australia3994695► subscribe
Australia694946► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc